Barcode assessment project demonstrates the ground gained in meeting serialization-readiness requirements for supply chain transparency
How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.
How personalized interventions can help boost the omnichannel experience for patient hubs—and drive engagement and impact adherence in outcomes.
The packaging and shipping of dangerous goods (DG) adds further challenges to the distribution pressures brought about by the pandemic
Product commercialization in Canada is by no means simple, but the end result presents its advantages
Questions and considerations for pharmaceutical companies in designing and executing strategies to curb the incidence of fake drugs.
When identifying a third-party service provider for ground transport of pharmaceutical freight, it is essential that the shipper partner with a company equipped with the expertise and technologies to plan for and monitor necessary shipments as well as respond to issues that may compromise the freight along its journey.
The top criteria to consider when evaluating and choosing the right airfreight container that can efficiently protect pharma’s cold chain
Although AI has simplified various market access processes, this technology does also present its share of barriers, so what can be done to find a happy medium?
How to best plan out and implement a marketing data hub as a key tool to harnessing today’s omnichannel transformation in pharma
From research and development to the clinical trials phase, pre-conditioning gel packs and PCMs prior to transport, Polar Leasing temperature-controlled chamber rentals are the perfect on-site solution for temporary refrigeration anywhere throughout the cold chain. Learn about our -30C Walk-In Freezer and its features now.
Five strategies to help pharma companies improve their return on investment from adherence-promoting initiatives and drive positive health outcomes for patients
With the standard constantly evolving across the pharma sector, the latest version can help bring benefits to the regulatory process.
Industrialized collaboration is critical to taking next-generation cell and gene therapies to the next level—if companies can build on pandemic-partnering momentum
What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?
Disruption is the order of the day to create a more individual-centric hub experience from the patient’s point of view
***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022**
What stands between pharma and other industries when it comes to remaining vigilant?
While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.
Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals
As the State Drug Pricing Transparency Program expands, what does that mean for manufacturers? Jesse Mendelsohn, Vice President, Centers of Excellence for Model N, the leader in cloud revenue management solutions for life science companies, discusses challenges for manufacturers as the State Price Transparency Program expands how they should plan for this change and the solutions they will need.
Vendor relationships are best supported by practices that emphasize efficiency, visibility, and the streamlining of the invoice to pay process
A prediction of how this shift toward patient-centric care may look.
If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
Drug shortages are inevitable—being caught off guard isn’t. The best ways distributors can use and position data to drive today’s inventory solutions
Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.